Massachusetts GLP 1 coverage for weight loss halves after insurers pull back

Massachusetts GLP 1 coverage for weight loss shrank by about half in early 2026, and the debate over that cut is back in the Boston Globe. A letter published on October 20 cited state data showing that commercially insured residents using the drugs for weight loss fell 52 percent after many insurers stopped paying. The figures come from the state Health Policy Commission, which released them on September 17. Diabetes coverage largely continues. The open question is what happened to the people who lost coverage, and whether the savings will last.

What the Health Policy Commission found

The Health Policy Commission is the state agency that tracks health care spending in Massachusetts. Its pharmacy policy office showed a preview of GLP 1 trends at a board meeting on September 17, ahead of that office's first annual report. Between the last quarter of 2025 and the first quarter of 2026, about 112,000 fewer commercially insured members had a GLP 1 drug covered for weight loss, a fall of roughly 52 percent, according to a report on the slides by State House News Service. The timing matches the new plan year in January, when several large insurers redrew Massachusetts GLP 1 coverage and ended routine payment for GLP 1 weight loss drugs such as Wegovy and Zepbound.

The money side explains why insurers acted. Gross spending on GLP 1 drugs for commercially insured residents passed $2.3 billion in 2025 before rebates and discounts, and net spending came to nearly $1 billion, the commission said. About three quarters of the 2025 spending was for weight loss, and that part had grown by an average of about 99.5 percent a year from 2019 to 2025. With fewer people covered, the commission projects annualized 2026 spending of about $662 million. The data has limits. It counts only prescriptions billed to commercial insurance, so it cannot see anyone who kept taking a drug by paying cash, and it leaves out MassHealth and the Group Insurance Commission, the plan for state workers.

Which insurers dropped weight loss coverage

Blue Cross Blue Shield of Massachusetts and Point32Health, the parent of Harvard Pilgrim and Tufts Health Plan, ended blanket coverage of GLP 1 drugs for obesity in January. Mass General Brigham Health Plan also stopped, and the two public plans, MassHealth and the Group Insurance Commission, limited weight loss coverage as well. Many plans now let an employer add obesity coverage back for a higher charge, and many employers chose not to, the Globe reported. The result shows in the payer data. At Blue Cross, the share of members with weight loss GLP 1 coverage fell from 6.1 percent at the end of 2025 to 3.7 percent in the first quarter of 2026.

At Blue Cross, the share of members with weight loss GLP 1 coverage fell from 6.1 percent at the end of 2025 to 3.7 percent in the first quarter of 2026.

Insurers said the cuts were about cost, and their finances have since improved. Blue Cross reported operating income of $53 million in the first half of 2026 after two years of losses, while Point32Health reported nearly $125 million after a $96 million loss a year earlier, according to the Globe. Lora Pellegrini, who leads the Massachusetts Association of Health Plans, put the blame on drug makers: "The drug companies need to lower their prices." Patients see it differently. One Harvard Pilgrim member who lost coverage told the Globe the change was "a terrible injustice." Massachusetts is not the only payer to draw this line, as our report on Medi-Cal ending weight loss coverage shows.

Out of pocket costs and who pays now

For people who still have Massachusetts GLP 1 coverage, the bill at the counter has been fairly steady. In 2025 the average monthly cost sharing for an insured member was $78 for weight loss use and $66 for diabetes use, mostly copays, and the commission said those levels have generally held for several years. Members paid a total of $136.3 million in cost sharing on weight loss prescriptions that year and $45.9 million on diabetes prescriptions. For people who lost coverage, the picture is blank. The data cannot show whether they stopped treatment, changed channel or paid out of pocket. "I do wonder a lot about what happened to those folks," commission analyst Amanda Katchmar said, as quoted by the Globe.

Cash prices for approved drugs have dropped as makers sell straight to patients, which may explain part of the shift, though the commission did not measure it. Deputy director Sarah Shoemaker-Hunt said "manufacturers keep coming up with new direct-to-consumer models." Readers comparing routes can see how list, net, cash and copay figures differ in our guide to the four prices of one pen. Cheaper routes are not all equal. Compounded copies are not FDA approved products, and a low price says nothing about quality or sterility. The commission also expects at least 12 new GLP 1 drugs to launch by 2030, which could push net prices down further, though it said the biggest brands have patent protection that runs to 2041.

Why the letter wants coverage restored

The October 20 letter, from Dorchester resident Genevieve Guntrum Forster, argues that the cut may cost the state more later. Her reasoning is that people who lose access may go untreated for obesity and develop the chronic conditions linked to it, so it may make more sense to pay for the drugs up front and track whether spending on heart disease and diabetes falls. She asks the state to keep coverage for patients who meet evidence based criteria and to find savings elsewhere, as set out in the published letter. That view has support inside the commission. Board member Chris Leibman said "health care is an investment" and asked for future work on the drugs' wider benefits.

The other side of the argument is the short term budget. Insurers point to years of losses driven by fast growth in GLP 1 use, and the long term savings the letter describes have not been shown in Massachusetts data. Prices may change the math. Kiame Mahaniah, the state's secretary of health and human services, said in March that he would "be really surprised if within two years, we don't see a major price crash," and he predicted a return to full coverage within two to three years. That is a forecast, not a plan. Until prices fall or insurers reverse course, Massachusetts GLP 1 coverage for weight loss often depends on whether an employer pays extra for it.

Conclusion

Massachusetts GLP 1 coverage for weight loss fell by about half in one quarter, with about 112,000 fewer insured people covered, once large insurers ended routine payment in January. Diabetes coverage continues, and copays for insured members have stayed steady. What the data cannot show is how many people stopped treatment or found another way to pay. The commission's first annual report should add detail. This story explains coverage rules and is not medical advice.